回复

Ki-67 是 PO、AFU1 和 OS IA2 分析中的预后生物标志物，证实了 Ki-67 作为 EBC 预后标志物的作用。^1-4

上次审阅日期：2024年1月30日

参考文献

1. Harbeck N, Johnston S, Fasching P, et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. Poster presented at: 43rd Annual San Antonio Breast Cancer Symposium (SABCS Virtual); December 8-11, 2020. Accessed October 3, 2021. http://www.sabcs.org/Portals/SABCS2016/PD2%2001%20Nadia%20Harbeck.pdf?ver=2021-08-29-125001-927

2. O'Shaughnessy J, Rastogi P, Harbeck N, et al; monarchE Investigators. Adjuvant abemaciclib combined with Endocrine Therapy (ET): updated results from monarchE. Poster presented at: European Society of Medical Oncology (ESMO Virtual Plenary); October 14-15, 2021. Accessed September 5, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/adjuvant-abemaciclib-combined-with-endocrine-therapy-et-updated-results-from-monarche

3. Harbeck N, Rastogi P, Martin M, et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571-1581. https://doi.org/10.1016/j.annonc.2021.09.015

4. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Cancer Res. 2023;83(5 suppl):GS1-09. American Association for Cancer Research abstract GS1-09. https://doi.org/10.1158/1538-7445.SABCS22-GS1-09